EHA24 Congress: Novel Agent Under Study in Combination Therapies for Myeloma
Posted: Friday, June 21, 2019
Early-phase research has shown that a novel cereblon E3 ligase modulator, known as iberdomide, appears to be safe and active when joined with dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma who failed to respond (or no longer respond) to multiple prior therapies. Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, and colleagues presented these phase Ib/IIa dose-escalation study findings at the 24th European Hematology Association (EHA24) Congress in Amsterdam (Abstract S1603).
“Clinical activity occurred early and was observed across all dose levels,” the investigators commented, with 20 of 51 patients still on treatment. This ongoing study is also evaluating iberdomide in combination with daratumumab or bortezomib in this patient population.
As of January 2019, 58 patients had been treated with iberdomide plus dexamethasone as part of this multicenter trial. All patients had relapsed or refractory multiple myeloma and had received at least two prior regimens (median of five), including lenalidomide and/or pomalidomide and a proteasome inhibitor. Within 60 days of their last therapy, all patients had experienced disease progression.
The median duration of therapy was 12+ weeks, and the doses of iberdomide ranged from 0.3 to 1.2 mg. Grade 3 or 4 adverse events were reported in 72% of patients. Specifically, the grade 3 or 4 adverse events observed were neutropenia (26% of patients), thrombocytopenia (11%), and neuropathy (2%). Three patients discontinued treatment as a result of adverse events.
Of the 51 patients evaluated for response, 1 had a very good partial response, 15 had a partial response, and 19 had stable disease. The disease control rate was 88% (45 patients).
Disclosure: The study authors’ disclosure information may be found at ehaweb.org.
